New eye injection dose tested to halt diabetic vision threat
NCT ID NCT07118670
Summary
This study is testing the safety and effectiveness of a higher dose (8mg) of an existing eye injection medicine called aflibercept. It aims to control a severe form of diabetic eye disease called proliferative diabetic retinopathy (PDR) in 40 patients over two years. The goal is to see if this dose can better improve the severity of the eye disease and prevent it from worsening, which could help preserve vision.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROLIFERATIVE DIABETIC RETINOPATHY (PDR) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Retina Consultants of Texas
Bellaire, Texas, 77401, United States
-
Retina Consultants of Texas - Austin Retina Associates
Austin, Texas, 78705, United States
-
Retina Consultants of Texas - San Antonio
San Antonio, Texas, 78240, United States
Conditions
Explore the condition pages connected to this study.